Muscarinic M1 agonists in the treatment of Alzheimer's disease

A. D. Korczyn*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


The treatment of Alzheimer's disease attempts to correct cholinergic deficiency in the brain. In addition to the established, but restricted, efficacy of acetylcholinesterase inhibitors, attempts are being made to develop agents which will stimulate muscarinic receptors directly. This approach is logical and was found efficacious in several animal models of the disease; however none of these agents succeeded in clinical studies. Several reasons might account for this failure, which are discussed, as well as the prospects for the future.

Original languageEnglish
Pages (from-to)2259-2267
Number of pages9
JournalExpert Opinion on Investigational Drugs
Issue number10
StatePublished - 2000


  • Alzheimer's disease
  • Cholinesterase inhibitors
  • Cholinomimetics
  • Muscarinic agonists
  • Therapy


Dive into the research topics of 'Muscarinic M1 agonists in the treatment of Alzheimer's disease'. Together they form a unique fingerprint.

Cite this